Chengbin Wu (CEO of EpimAb)
March 22, 2021 07:00 PM EDTUpdated March 22, 09:22 PM
China

Trans-Pa­cif­ic bis­pe­cif­ic play­er caps 'very chal­leng­ing' pan­dem­ic year with $120M to gain a foothold among the gi­ants

Amber Tong

Senior Editor

It’s a nar­ra­tive that we’ve seen over and over again this past year: Covid-19 threw a mon­key wrench in­to clin­i­cal tri­al plans of drugs in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times